Providence researchers share cancer discoveries at 2025 ASCO meeting

Thursday, May 29, 2025

Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are helping shape the future of cancer care at the 2025 ASCO Annual Meeting in Chicago.

This premier event brings together leading oncologists, researchers and health care professionals, who share breakthroughs in cancer immunotherapy, emerging treatments and clinical best practices, including AI platforms to accelerate discovery and personalized care.

Find out which Providence experts are contributing to the 2025 annual meeting and get a glimpse into the studies driving the next wave of cancer research.

Rapid Oral Abstract Sessions

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract 3010: Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001)

Authors: Rachel Sanborn, et al.

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Abstract 4019: 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors

Authors: Rachel Sanborn, et al.

Gynecologic Cancer

Abstract 5516: A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial

Authors: Christopher Darus, et al.

Oral Abstract Sessions

Genitourinary Cancer—Kidney and Bladder

Abstract 4508: ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study

Authors: Brendan Curti, et al.

Melanoma/Skin Cancers

Abstract 9506: DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results

Authors: Brendan Curti, et al.

Poster Sessions

Head and Neck Cancer

Abstract 6084: Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma

Authors: R. Bryan Bell, Rom Leidner, Marka Crittenden, Kristina Young, Thomas Duhen, Brian Piening, Michael Gough, Bernard Fox, et al.

Breast Cancer

Abstract 549: Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts

Authors: Brian Piening, Carlo Bifulco, et al.

Abstract 556: Association of genetic predisposition to low-grade systemic inflammation with cancer-related fatigue in women receiving chemotherapy for non-metastatic breast cancer in URCC07012 and URCC10055.

Authors: Alison Conlin, et al.

Melanoma/Skin Cancers

Abstract TPS9600: A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma

Authors: Brendan Curti, et al.

Developmental Therapeutics—Immunotherapy

Abstract TPS2685: A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors

Authors: Christopher Darus, et al.

Developmental Therapeutics—Immunotherapy

Abstract TPS2678: A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors

Authors: Rom Leidner, et al.

Breast Cancer

Abstract 554: Association of ImPrintTN signature with survival outcomes by race in basal-type triple negative breast cancer (TNBC): FLEX registry analysis

Authors: David Page, et al.

Lung Cancer

Abstract TPS8126: A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC)

Authors: Rachel Sanborn, et al.

Abstract 8598: Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors

Authors: Matthew Taylor, et al.

Publication Only

Breast Cancer

Abstract e13048: Development of a highly sensitive ctDNA assay to map the evolution of metastatic breast cancer

Authors: David Page, Alison Conlin, Brian Piening, et al.

Abstract e18101: Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response

Authors: Marka Crittenden, Brian Piening, Rom Leidner, Kristina Young, Thomas Duhen, R. Bryan Bell, et al.

Earle A. Chiles Research Institute and Providence Cancer Institute

Providence Cancer Institute is a leading provider of cancer care in Oregon and a global leader in immuno-oncology. Through its research division, the Earle A. Chiles Research Institute, patients have access to state-of-the-art genomic sequencing, adoptive cellular therapies and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group and industry-sponsored trials. Learn more about research at Earle A. Chiles Research Institute.